Contact
Please use this form to send email to PR contact of this press release:
SIGA Completes Enrollment and Dosing in Final Cohort of Phase I Study of IV Formulation of TPOXX® (tecovirimat) to Treat Smallpox
TO:
Please use this form to send email to PR contact of this press release:
SIGA Completes Enrollment and Dosing in Final Cohort of Phase I Study of IV Formulation of TPOXX® (tecovirimat) to Treat Smallpox
TO: